九洲藥業股票討論區

Despite a recent share price drop, the company's long-term performance and EPS growth remain impressive. The market appears pessimistic, but if fundamentals indicate sustainable growth, the current sell-off could be a potential opportunity.

The company's low P/E ratio of 14.1x, compared to the market average in China, is due to expectations of limited future growth. The share price is unlikely to rise significantly in the near future under these circumstances.